EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

Phase

Condition

Osteoporosis

Treatment

Placebo

EffCaMgCit

Clinical Study ID

NCT05998863

STU-2023-0340

Ages 21-99
All Genders
Accepts Healthy Volunteers

Study Summary

Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteoporosis), hypomagnesemia (magnesium deficiency) and increased risk of chronic kidney disease (CKD). The current trial represents the investigators ongoing effort to discern whether these complications could be averted by effervescent calcium magnesium citrate (EffCaMgCit).

Eligibility Criteria

Inclusion

Inclusion Criteria:

Ambulatory adult subjects (> 21 years of age) of either gender of any ethnicity
Must have taken PPI (omeprazole or equivalent ≥ 20 mg/day, ≥ three times per week,for at least 2 months)
Expected to continue at a similar dosage
Stage 1 hypertension (with systolic blood pressure <140 and diastolic <90)
Controlled diabetes mellitus Type II with HbA1C less than 7%

Exclusion

Exclusion Criteria:

End-stage renal failure on dialysis
Hypercalcemia,
Hypophosphatemia (serum P < 2.5 mg/dL)
Hypertension stage 2 or higher
Diabetes Type II with HbA1C ≥ 7%
Treatment with adrenocorticosteroids, diuretics, non-steroidal anti-inflammatoryagents - - Regular dose of magnesium supplements, bisphosphonate, teriparatide,denosumab or selective estrogen receptor modulators
Required to take calcium

Inclusion/exclusion of other drugs or conditions will be considered on an individual basis.

Study Design

Placebo

April 19, 2024

December 31, 2026

Study Description

In the current proposal, the investigators wish to conduct a 1-year treatment trial, directed at obtaining more definitive evidence that EffCaMgCit overcomes all three complications of PPI.

Aim 1. To test the hypothesis that EffCaMgCit would prevent/treat osteoporosis, by suppressing parathyroid function and bone resorption, thereby stabilizing bone mineral density (BMD). The critical endpoint will be overall change in BMD T-Score and Z-Score from baseline to the end of study. Secondary endpoints will be the change in serum PTH and C-terminal telopeptide (CTX).

Aim 2. To test the hypothesis that EffCaMgCit would prevent/treat hypomagnesemia/magnesium deficiency, by providing bioavailable magnesium. The critical endpoint will be the overall change in the fractional excretion of magnesium (FEMg) and free muscle magnesium by MRS from baseline to the end of study. Secondary endpoints will be the change in serum and urinary magnesium.

Aim 3. To test the hypothesis that EffCaMgCit would reduce the risk of CKD during PPI use by averting putative hypomagnesemia/magnesium deficiency and neutralizing acid load. The investigators propose that PPI causes hypomagnesemia/magnesium deficiency and confers an acid load, - factors implicated for incident CKD and its progression. EffCaMgCit is expected to avert incident CKD by providing bioavailable magnesium and alkali load. Critical endpoints will be the overall change in endogenous creatinine clearance, urinary alpha-1 microglobulin, and a measure of acid-base status.

Connect with a study center

UT Southwestern Medical Center
Dallas, Texas 75390
United States
Active - Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas 75390-9107
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.